|
KR20170005191A
(ko)
|
2009-01-06 |
2017-01-11 |
큐어론 엘엘씨 |
이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법
|
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
|
SMT201700026T1
(it)
|
2009-09-03 |
2017-03-08 |
Bristol Myers Squibb Co |
Chinazoline come inibitori dei canali degli ioni potassio
|
|
US9511125B2
(en)
|
2009-10-21 |
2016-12-06 |
Curemark Llc |
Methods and compositions for the treatment of influenza
|
|
US8703941B2
(en)
|
2011-01-10 |
2014-04-22 |
Nimbus Iris, Inc. |
IRAK inhibitors and uses thereof
|
|
GB201114212D0
(en)
|
2011-08-18 |
2011-10-05 |
Ucb Pharma Sa |
Therapeutic agents
|
|
WO2013068592A1
(en)
*
|
2011-11-10 |
2013-05-16 |
Fondation Jerome Lejeune |
Inhibitors of cystathionine beta synthase to reduce the neurotoxic overproduction of endogenous hydrogen sulfide
|
|
AR090037A1
(es)
|
2011-11-15 |
2014-10-15 |
Xention Ltd |
Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
|
|
CN104582705A
(zh)
*
|
2012-01-10 |
2015-04-29 |
林伯士艾瑞斯公司 |
白介素-1受体相关激酶(irak)抑制剂和其用途
|
|
CA2861464C
(en)
*
|
2012-01-25 |
2018-03-06 |
Proteostasis Therapeutics, Inc. |
Proteasome activity modulating tricyclic compounds
|
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
|
EP2671575A1
(en)
*
|
2012-06-04 |
2013-12-11 |
Universität Regensburg |
Ras inhibitors
|
|
SMT201800369T1
(it)
|
2012-06-11 |
2018-09-13 |
Bristol Myers Squibb Co |
Profarmaci di acido fosforamidico di 5-[5-fenil-4-piridin-2-il-metilammino)chinazolin-2-il}piridina-3-solfonammide
|
|
HK1210696A1
(en)
|
2012-07-11 |
2016-05-06 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
WO2014011906A2
(en)
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
MX2015002887A
(es)
*
|
2012-09-06 |
2015-07-06 |
Plexxikon Inc |
Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
|
|
US9914730B2
(en)
*
|
2012-09-28 |
2018-03-13 |
Cancer Research Technology Limited |
Azaquinazoline inhibitors of Atypical protein Kinase C
|
|
GB201217704D0
(en)
*
|
2012-10-03 |
2012-11-14 |
Ucb Pharma Sa |
Therapeutic agents
|
|
US20140136295A1
(en)
|
2012-11-13 |
2014-05-15 |
Apptio, Inc. |
Dynamic recommendations taken over time for reservations of information technology resources
|
|
JP2016505012A
(ja)
|
2013-01-10 |
2016-02-18 |
ニンバス アイリス， インコーポレイテッド |
Ｉｒａｋ阻害剤およびその使用
|
|
EP2956470A4
(en)
*
|
2013-02-15 |
2016-12-07 |
Univ Michigan Regents |
COMPOSITIONS AND METHODS RELATED TO PREVENTING DOT1L RECRUITMENT BY MLL FUSION PROTEINS
|
|
KR20150130389A
(ko)
*
|
2013-03-13 |
2015-11-23 |
더 리젠츠 오브 더 유니버시티 오브 미시간 |
티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법
|
|
CN104119343A
(zh)
*
|
2013-04-25 |
2014-10-29 |
苏州科捷生物医药有限公司 |
2-三氟甲基噻二唑类化合物及其用途
|
|
BR112016006319A2
(pt)
|
2013-09-27 |
2017-08-01 |
Nimbus Iris Inc |
inibidores de irak e usos dos mesmos
|
|
TWI648281B
(zh)
*
|
2013-10-17 |
2019-01-21 |
日商安斯泰來製藥股份有限公司 |
含硫二環式化合物
|
|
JP2017001954A
(ja)
*
|
2013-11-08 |
2017-01-05 |
石原産業株式会社 |
含窒素飽和複素環化合物
|
|
CN104892589A
(zh)
*
|
2014-03-07 |
2015-09-09 |
中国科学院上海药物研究所 |
一类杂环化合物、其制备方法和用途
|
|
JP2017507969A
(ja)
*
|
2014-03-11 |
2017-03-23 |
ゴーダーヴァリ バイオリファイナリーズ リミテッド |
がん幹細胞標的化合物
|
|
WO2016040330A1
(en)
*
|
2014-09-09 |
2016-03-17 |
The Regents Of The University Of Michigan |
Thienopyrimidine and thienopyridine compounds and methods of use thereof
|
|
WO2016081732A1
(en)
|
2014-11-19 |
2016-05-26 |
Memorial Sloan-Kettering Cancer Center |
Thienopyrimidines and uses thereof
|
|
CN104592248A
(zh)
*
|
2014-12-31 |
2015-05-06 |
芜湖杨燕制药有限公司 |
一种4-氯-6-取代噻吩并[2,3-d]嘧啶化合物的制备方法
|
|
WO2016197027A1
(en)
|
2015-06-04 |
2016-12-08 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with mll proteins
|
|
AR104020A1
(es)
*
|
2015-06-04 |
2017-06-21 |
Kura Oncology Inc |
Métodos y composiciones para inhibir la interacción de menina con proteínas mill
|
|
GB201519573D0
(en)
|
2015-11-05 |
2015-12-23 |
King S College London |
Combination
|
|
EP4643952A3
(en)
|
2016-01-26 |
2026-01-14 |
Memorial Sloan Kettering Cancer Center |
Targeting chromatin regulators for inhibiting leukemogenic gene expression in npm1
|
|
CN109640987B
(zh)
|
2016-03-16 |
2022-12-02 |
库拉肿瘤学公司 |
Menin-mll的桥联双环抑制剂及使用方法
|
|
CN109152784B
(zh)
*
|
2016-03-16 |
2021-12-28 |
库拉肿瘤学公司 |
经取代的menin-mll抑制剂及使用方法
|
|
WO2017192543A1
(en)
|
2016-05-02 |
2017-11-09 |
Regents Of The University Of Michigan |
Piperidines as menin inhibitors
|
|
WO2017207387A1
(en)
|
2016-05-31 |
2017-12-07 |
Bayer Pharma Aktiengesellschaft |
Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
|
|
WO2018024602A1
(en)
|
2016-08-04 |
2018-02-08 |
Bayer Aktiengesellschaft |
2,7-diazaspiro[4.4]nonanes
|
|
CA3033239A1
(en)
|
2016-09-14 |
2018-03-22 |
Janssen Pharmaceutica Nv |
Spiro bicyclic inhibitors of menin-mll interaction
|
|
CN109689663B
(zh)
|
2016-09-14 |
2023-04-14 |
詹森药业有限公司 |
Menin-mll相互作用的螺二环抑制剂
|
|
US12084462B2
(en)
|
2016-09-14 |
2024-09-10 |
Janssen Pharmaceutica Nv |
Spiro bicyclic inhibitors of menin-MLL interaction
|
|
MA46228A
(fr)
|
2016-09-14 |
2019-07-24 |
Janssen Pharmaceutica Nv |
Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
|
|
EP3532464A4
(en)
|
2016-10-28 |
2020-07-08 |
Icahn School of Medicine at Mount Sinai |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF EZH2 MEDIATION CANCER
|
|
JP2020514252A
(ja)
|
2016-12-08 |
2020-05-21 |
アイカーン スクール オブ メディスン アット マウント シナイ |
Ｃｄｋ４／６媒介性がんを治療するための組成物および方法
|
|
BR112019012106A2
(pt)
*
|
2016-12-15 |
2019-10-29 |
Janssen Pharmaceutica Nv |
inibidores de azepano de interação menin-mill
|
|
EA201991448A1
(ru)
|
2017-01-06 |
2019-12-30 |
Янссен Фармацевтика Нв |
Азепановые ингибиторы взаимодействия менин-mll
|
|
EA038388B1
(ru)
*
|
2017-01-16 |
2021-08-19 |
Кура Онколоджи, Инк. |
Замещенные ингибиторы менина-mll и способы применения
|
|
CN110691779B
(zh)
*
|
2017-03-24 |
2023-10-10 |
库拉肿瘤学公司 |
治疗血液系统恶性肿瘤和尤因肉瘤的方法
|
|
CA3058448A1
(en)
|
2017-03-31 |
2018-10-04 |
The Regents Of The University Of Michigan |
Piperidines as covalent menin inhibitors
|
|
US11542248B2
(en)
|
2017-06-08 |
2023-01-03 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with MLL proteins
|
|
US11649251B2
(en)
|
2017-09-20 |
2023-05-16 |
Kura Oncology, Inc. |
Substituted inhibitors of menin-MLL and methods of use
|
|
US11396517B1
(en)
|
2017-12-20 |
2022-07-26 |
Janssen Pharmaceutica Nv |
Exo-aza spiro inhibitors of menin-MLL interaction
|
|
KR20200101389A
(ko)
|
2017-12-20 |
2020-08-27 |
얀센 파마슈티카 엔.브이. |
메닌-mll 상호작용의 엑소-아자 스피로 억제제
|
|
CA3092677A1
(en)
|
2018-03-06 |
2019-09-12 |
Icahn School Of Medicine At Mount Sinai |
Serine threonine kinase (akt) degradation / disruption compounds and methods of use
|
|
US11325921B2
(en)
|
2018-03-30 |
2022-05-10 |
Sumitomo Dainippon Pharma Co., Ltd. |
Optically active crosslinked cyclic secondary amine derivative
|
|
CA3104298A1
(en)
|
2018-06-21 |
2019-12-26 |
Icahn School Of Medicine At Mount Sinai |
Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
|
|
BR112021006273A2
(pt)
|
2018-10-03 |
2021-07-06 |
Agios Pharmaceuticals Inc |
inibidores de menin de pequenas moléculas
|
|
CN118908962A
(zh)
|
2019-05-06 |
2024-11-08 |
西奈山伊坎医学院 |
作为hpk1的降解剂的异双功能化合物
|
|
TW202126636A
(zh)
|
2019-09-30 |
2021-07-16 |
美商阿吉歐斯製藥公司 |
作為ｍｅｎｉｎ抑制劑之六氫吡啶化合物
|
|
WO2021063346A1
(zh)
*
|
2019-09-30 |
2021-04-08 |
上海迪诺医药科技有限公司 |
Kras g12c抑制剂及其应用
|
|
JP7554829B2
(ja)
|
2019-12-19 |
2024-09-20 |
ヤンセン ファーマシューティカ エヌ．ベー． |
置換直鎖スピロ誘導体
|
|
CN111297863B
(zh)
*
|
2020-03-30 |
2021-06-25 |
四川大学华西医院 |
menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
|
|
WO2021207310A1
(en)
|
2020-04-08 |
2021-10-14 |
Agios Pharmaceuticals, Inc. |
Menin inhibitors and methods of use for treating cancer
|
|
TW202204333A
(zh)
|
2020-04-08 |
2022-02-01 |
美商阿吉歐斯製藥公司 |
Menin抑制劑及治療癌症之使用方法
|
|
US12103924B2
(en)
|
2020-06-01 |
2024-10-01 |
Icahn School Of Medicine At Mount Sinai |
Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
|
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
|
WO2022086937A1
(en)
*
|
2020-10-21 |
2022-04-28 |
Icahn School Of Medicine At Mount Sinai |
Heterobifunctional compounds as degraders of enl
|
|
MX2023013174A
(es)
|
2021-05-08 |
2023-11-30 |
Janssen Pharmaceutica Nv |
Derivados espiro sustituidos.
|
|
EP4334320A1
(en)
|
2021-05-08 |
2024-03-13 |
JANSSEN Pharmaceutica NV |
Substituted spiro derivatives
|
|
WO2022253167A1
(en)
|
2021-06-01 |
2022-12-08 |
Janssen Pharmaceutica Nv |
SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES
|
|
CN117425659A
(zh)
|
2021-06-03 |
2024-01-19 |
詹森药业有限公司 |
哒嗪或被螺环胺取代的1,2,4-三嗪
|
|
CA3220099A1
(en)
|
2021-06-17 |
2022-12-22 |
Wei Cai |
(r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cance
|
|
WO2023056589A1
(en)
|
2021-10-08 |
2023-04-13 |
Servier Pharmaceuticals Llc |
Menin inhibitors and methods of use for treating cancer
|
|
CN120529900A
(zh)
|
2022-11-24 |
2025-08-22 |
奥莱松基因组股份有限公司 |
用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合
|